In examining why some advanced melanoma patients respond so well to the experimental immunotherapy MK-3475, while others have a less robust response, researchers at Mayo Clinic in Florida found that the size of tumors before ...
Jun 2, 2014
0
1
(HealthDay)—An affinity-enhanced T cell receptor specific for the human leukocyte antigen-A2 restricted melanoma gp 100 peptide fused to an anti-CD3 antibody fragment, IMCgp100, seems promising for advanced melanoma, according ...
Apr 9, 2014
0
0
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial ...
Mar 4, 2014
0
0
With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in The Journal of Nuclear Medicine highlights the potential ...
Jan 7, 2014
0
0
(Medical Xpress)—The most devastating feature of cancer is that it often spreads throughout the human body and forms secondary tumors also known as metastases. One of the most aggressive metastatic cancers with no currently ...
Oct 30, 2013
0
0
A Yale-led team of researchers has solved a biological mystery about the common genesis of many serious diseases such as asthma and metastatic melanoma, identifying the first known pathway by which their cellular functions ...
Aug 27, 2013
0
0
Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current ...
Jun 11, 2013
0
0
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic ...
Nov 14, 2012
0
0
Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.
Oct 1, 2012
0
0
(HealthDay)—In the first-line treatment of metastatic melanoma, interleukin-21 (IL-21) shows an overall response rate (ORR) of 22.5 percent and warrants further study, according to research published online Aug. 20 in the ...
Aug 23, 2012
0
0
